Chimeric immunoglobulin-T-cell receptor (IgTCR)-modified T cells (“designer T cells”) kill tumor cells based on antibody-redirected recognition of tumor-associated antigen. Anti-carcinoembryonic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results